

Leslie W Chinn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8678314/publications.pdf>

Version: 2024-02-01

7
papers

264
citations

1478280

6
h-index

1719901

7
g-index

7
all docs

7
docs citations

7
times ranked

293
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|---|-----|-----------|
| 1 | Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of <sc>DDI</sc>. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 269-277. | 2.3 | 48 |
| 2 | Antibody-mediated activation of the FGFR1/Klotho ² complex corrects metabolic dysfunction and alters food preference in obese humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28992-29000. | 3.3 | 55 |
| 3 | Understanding the Effect of Hydroxypropyl β -Cyclodextrin on Fenebrutinib Absorption in an Itraconazole β -Fenebrutinib Drug β -Drug Interaction Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1224-1232. | 2.3 | 8 |
| 4 | Physiologically β -Based Pharmacokinetic Model β -Informed Drug Development for Fenebrutinib: Understanding Complex Drug β -Drug Interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 332-341. | 1.3 | 17 |
| 5 | Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double β -Blind, Phase <sc>II</sc> Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1435-1446. | 2.9 | 83 |
| 6 | Absence of Pharmacokinetic Interactions between the Bruton TM s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 202-207. | 1.3 | 4 |
| 7 | Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC β 0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1020-1028. | 2.3 | 49 |